FOAM for EM pharmacists November
A weekly roundup of FOAMed content for EM pharmacists.
Jon-Emile S. Kenny MD [@heart_lung] What if I told you that in acute pulmonary thromboembolism [PE] that the initiation of intravenous norepinephrine [NE] decreases the calculated pulmonary vascular resistance [cPVR]? Would you believe me? Certainly, you would trust that an infusion of a thrombolytic does so. Of great interest, both NE and thrombolytics decrease the cPVR [… read more] The post
EM Journal Update: Effects of Tranexamic Acid on Death, Disability, Vascular Occlusive Events and Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-Controlled Trial: Core EM
Tranexamic acid for significant traumatic brain injury (The CRASH-3 trial): Statistical analysis plan for an international, randomized, double-blind, placebo-controlled trial. The Lancet, 2018 Background Head trauma is a leading cause
In patients post-myocardial infarction, does low dose colchicine compared with placebo, reduce ischaemic cardiovascular events?
Intramuscular naloxone works more quickly than intranasal administration of the same dose; however, there may be advantages to intranasal administration.
Clinical vignette A 45-year-old healthy male presents to the emergency department (ED) with a one-day history of back pain. The pain started while working out at the gym – he lifted a heavyweight above his head and felt a
Last weeks post:
For more posts related to FOAM for EM pharmacists November:
|New articles and evidence updates|